Vaccinia virus (VV) has been used extensively as a vaccine vehicle in the clinical application for infectious diseases and cancer. Previous studies have suggested that the unique potency of VVbased vaccine lies in its effective activation of innate immune system. However, how VV activates innate immune pathways remains largely unknown. In this study, we showed that VV elicited innate immune response through both TLR-dependent and -independent pathways. The TLR pathway was mediated by TLR2 and MyD88, leading to the production of pro-inflammatory cytokines, whereas activation of the TLR-independent pathway resulted in the secretion of IFN-β.
Introduction
Vaccinia virus (VV) belongs to a member of the Orthopoxvirus genus of the Poxviridae family that includes smallpox (variola) virus, monkeypox virus, cowpox virus, and ectromelia virus 1 . It is an enveloped, double-stranded DNA virus with a genome measuring about 200 Kb that encodes most of proteins required for cytoplasmic replication of the virus in host cells. VV is the most studied member of the poxvirus family and is responsible for the successful elimination of smallpox worldwide 2 . This success has led to the development of recombinant VV as a vaccine vehicle for other infectious diseases such as influenza, HIV and malaria [3] [4] [5] . Furthermore, VV has also been developed as a vaccine for cancer immunotherapy 6 . In most cases, immunization with recombinant vaccinia encoding a tumor antigen generates significantly greater immune responses than that with the corresponding protein or peptide epitopes mixed with standard adjuvants. So far, many poxviruses have been explored as tumor vaccine vectors and used in human clinical trials, including attenuated, replication-deficient poxviruses such as modified vaccinia Ankara, fowlpox and canarypox [7] [8] [9] [10] .
What then is responsible for the unique potency of VV as a vaccine vehicle? Using a model of peripheral T cell tolerance, which is analogous to clinically established cancer, we have recently shown that sustained stimulation of Toll-like receptors (TLRs) of the innate immunity is required for breaking established regulatory T cell (T Reg )-mediated CD8 T cell tolerance in vivo and that recombinant VV vaccine can provide TLR signals, leading to the reversal of T Regmediated tolerance, and protect mice from tumor challenge 11 . These results suggest that effective activation of innate immune system contributes to the unique potency of VV vaccine.
However, how VV activates innate immune pathways remains unknown. A clear understanding of the mechanisms underlying innate immune response to VV will help us design effective vaccines.
The phylogenetically conserved innate immune system represents the first line of defense against invading pathogens through recognition of pathogen-associated molecular patterns (PAMPs) by a set of receptors called pattern recognition receptors (PRRs) 12 . TLRs are the best characterized family of PRRs and expressed mainly on macrophages and dendritic cells (DCs). Each of 12 TLRs identified in mammals so far appears to recognize a unique set of For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From PAMPs including peptidoglycan (PGN, TLR2 ligand), dsRNA (TLR3 ligand), lipopolysaccharide (LPS, TLR4 ligand), and CpG DNA (TLR9 ligand) 12 . Recogition of TLRs by PAMPs triggers signaling cascades leading to the induction of anti-microbial genes and inflammatory cytokines. In addition, emerging evidence supports the existence of TLR-independent innate immune recognition of pathogens 13 .
In this study, we provided evidence that VV activated innate immunity through both TLRdependent and -independent pathways, leading to the production of pro-inflammatory cytokines and interferon-β (IFN-β) in vitro and in vivo. The secretion of pro-inflammatory cytokines was mediated by TLR2 and dependent on the common TLR adaptor MyD88, whereas the production of IFN-β was through a TLR-independent pathway. Furthermore, we demonstrated that the TLR2/MyD88 innate immune pathway played an important role in shaping innate and adaptive immune responses to VV in vivo. In addition, both innate and adaptive immunity against VV infection in vivo was critically dependent on TLR-independent production of IFN-β. These results indicated that innate immune recognition of VV is mediated by TLR2 and showed that one pathogen can target both TLR and non-TLR innate immune pathways cooperatively to achieve efficient activation of the host's immune system. 
Vaccinia virus
The Western Reserve (WR) strain of VV was purchased from American Type Culture Collection.
The virus was grown in TK-143B cells and purified by centrifugation through a 35% sucrose cushion as described 11 . The titer of virus was determined by plaque assay on TK-143B cells and . Briefly, purified virus was resuspended in 1 µ g/ml 8-methoxypsoralen (Sigma) and then exposed to a 365 nm UV light source (UVP model UVGL-25) on ice for 3 min in a 24-well plate. For in vitro DC stimulations, both live VV and UV-inactivated VV were used at multiplicity of infection (m.o.i.) of 1. The dose of UV-VV was based on pre-inactivation titer. For in vivo studies, 1 x 10 7 pfu of live VV in 0.1 ml of PBS was injected into mice intravenously or intraperitoneally as described 11 .
DC culture
DCs were generated as described 11 . Briefly, femurs and tibiae of mice were harvested and bone marrow cells were flushed out with DC medium (RPMI-1640 with 5 % FBS, 2 mM L-glutamine, 10 mM HEPES, 50 µM β -mercaptoethanol, 100 IU/ml of penicillin and 100 IU/ml of streptomycin).
After lysis of red blood cells, the bone marrow cells were cultured in 6-well plates at a density of 3
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From x 10 6 /ml in 3 ml of DC medium in the presence of mouse GM-CSF (1,000 U/ml) and IL-4 (500 U/ml) (R & D Systems). GM-CSF and IL-4 were replenished on days 2 and 4. On day 5, DCs were harvested and same numbers of CD11c+ DCs at a density of 0.85 x 10 6 /ml were transferred onto a new 24-well plate in 2 ml of DC medium and incubated with the following stimuli in vitro:
LPS (Escherichia coli O26:B6, Sigma) at 100 ng/ml, PGN (S. aureus, Sigma) at 10 µg/ml, phosphorothioate-stabilized CpG ODN (oligodeoxynucleotide, 5'-TCCATGACGTTCCTGATGCT-3') (Integrated DNA Technologies) at 1 nM, poly (I:C) (Amersham Biosciences) at 100 µ g/ml, live or UV-VV at m.o.i of 1. The cells were then incubated for an additional 18 h at 37°C.
Supernatants were analyzed for cytokine production by ELISA.
Cytokine measurements by ELISA
Production of IL-1, IL-6, IL-12, IFN-α and IFN-β by the DCs in response to various stimuli was detected in culture supernatants or sera by ELISA kits according to manufacturer's standard protocols. IL-1β, IL-6, and IL-12p70 ELISA kits were purchased from Endogen Pierce, and IFN-α and IFN-β were obtained from PBL Biomedical Laboratories.
Proliferation assay
T cells were isolated from splenocytes using CD5-microbeads (Miltenyi Biotec). H-thymidine pulsing, the plates were harvested using a 96-well cell harvester and the 3 H-thymidine incorporation was counted using a 1205
Betaplate liquid scintillation counter (Wallac).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Antibodies and flow cytometry FITC-conjugated anti-CD11c, FITC-conjugated anti-IFN-γ, PE-conjugated anti-CD86, PE-Cy5-conjugated anti-CD8 antibodies were purchased from BD Pharmingen. FACScan (Becton Dickinson) was used for flow cytometry event collection, which was analyzed using CELLQuest software (Becton Dickinson).
Intracellular cytokine staining
To assess production of IFN-γ intracellularly, splenocytes were incubated with 1 µ g/ml of anti-CD3 and anti-CD28 (BD Pharmingen) antibodies and 5 µg/ml of Brefeldin A containing Golgi-Plug (BD PharMingen) for 4 hrs at 37 o C. Intracellular cytokine staining was performed as previously described. Briefly, the cells were first stained with anti-CD8 followed by fixation and permeabilization with Cytofix/Cytoperm (BD Pharmingen). The cells were subsequently stained intracellularly with anti-IFN-γ. Samples were acquired on a BD Biosciences FACSCalibur flow cytometer and analysis was performed using CellQuest software (BD Biosciences).
Ovary vaccinia virus titer assay
Viral load in the ovaries was measured by plaque forming assay as described 21 . Briefly, mice were sacrificed 3 days after infection, and ovaries were harvested and stored at -80 o C. Ovaries from individual mice were homogenized, freeze-thawed three times and sonicated. Serial dilutions were performed and the virus titers were then determined by plaque assay on confluent TK-143B cells.
Statistical analysis
Results are expressed as mean ± s.d.. Differences between groups were examined for statistical significance using student t-test. Figure 1C ), but no IFN-α ( Figure 1D ). This pattern of cytokine production was very similar to that of PGN, but not LPS or CpG. However, very different from PGN was that VV also induced high levels of IFN-β ( Figure 1E ). These results indicated that VV could stimulate DCs to produce both pro-inflammatory cytokines and IFN-β, but not IFN-α.
The induction of cytokine production by VV appeared to be independent of newly synthesized viral gene products after infection as similar levels of cytokines were induced by UV-VV ( Figure   1 ).
Production of pro-inflammatory cytokines is dependent on MyD88, whereas secretion of IFN-β is TLR-independent
We next examined if TLRs were involved in the recognition of VV by DCs. Since all TLR signaling is mediated by MyD88 and/or TRIF 12 , DCs deficient for MyD88 (MyD88 -/-) or TRIF (TRIF -/-) were tested for their ability to produce pro-inflammatory cytokines and IFN-β upon VV infection.
MyD88
-/-and TRIF -/-DCs were first produced from bone marrow cells of MyD88 -/-and TRIF -/-mice, respectively. Similar percentages of CD11c + DCs were generated from MyD88 -/-or TRIF -/-mice compared to the wild type (WT) control after 5 days of culture ( Figure S1 ), suggesting
MyD88-or TRIF-deficiency did not affect the efficiency of DC differentiation in vitro. Same numbers of CD11c + DCs from each group were stimulated with VV for 18 hr and the supernatants were assayed for the production of IL-6, IL-1 and IFN-β. MyD88 -/-DCs stimulated with VV showed greatly diminished levels of IL-6 ( Figure 2A ) and IL-1 ( Figure 2B ), whereas the production of IL-6
and IL-1 was not affected by the TRIF -/-DCs compared to the wild type (WT) DCs. By contrast, when stimulated with TLR3 ligand, poly (I:C), MyD88 -/-DCs produced similar levels of IL-6 compared to the WT control ( Figure 2C ), whereas TRIF -/-DCs produced little IL-6. This was consistent with the previous observation that cytokine production mediated by TLR3 is TRIFdependent, but MyD88-independent, and suggested the lack of IL-6 production by VV-stimulated MyD88 -/-DCs was not due to their inherent defect in cytokine production. Surprisingly, in contrast to IL-6 production, both MyD88 -/-and TRIF -/-DCs secreted similar levels of IFN-β upon VV infection compared to WT DCs ( Figure 2D ). These data indicated that VV-induced production of pro-inflammatory cytokines was TLR-mediated and dependent on MyD88, whereas the induction of IFN-β was independent of TLRs.
TLR2 is required for vaccinia virus-induced secretion of pro-inflammatory cytokines
We next determined which TLR mediated the MyD88-dependent production of pro-inflammatory cytokines. The similarity in the pattern of cytokine secretion between TLR2 ligand, PGN and VV suggested TLR2 as a likely candidate to mediate VV-induced production of pro-inflammatory cytokines. To test this hypothesis, we examined whether DCs defective for TLR2 (TLR2 -/-) secreted pro-inflammatory cytokines in response to VV infection. Like MyD88-or TRIF-deficiency, TLR2 deficiency did not appear to alter DC differentiation in vitro as similar percentages of CD11c + DCs were generated from TLR2 -/-mice compared to the WT control ( Figure S1 ). Similar to TLR2 -/-DCs treated with PGN, TLR2 -/-DCs stimulated with VV failed to secrete IL-6 ( Figure   3A ) or IL-1 ( Figure 3B ), whereas the production of IL-6 or IL-1 was not affected in TLR4 -/-or TLR9 -/-DCs in comparison to WT DCs upon VV infection. The lack of pro-inflammatory cytokine production by VV-stimulated TLR2 -/-DCs was not due to their inherent inability to secrete cytokines as TLR2 -/-DCs stimulated with TLR4 ligand, LPS, produced similar levels of IL-6 ( Figure 3A ) or IL-1 ( Figure 3B ) compared to the WT control. These data showed that induction of pro-inflammatory cytokines by VV was mediated through TLR2.
TLR2/MyD88 pathway is required for innate and adaptive immunity to vaccinia virus in vivo
Using DCs generated from bone marrow cells in vitro, we identified that VV-induced production of pro-inflammatory cytokines was mediated through TLR2 in a MyD88-dependent fashion. Here we examined the in vivo relevance of VV recognition by TLR2. WT, TLR2 -/-or MyD88 -/-mice were injected with 1 x 10 7 pfu of VV intravenously. 6 hr later, serum was harvested and assayed for IL-6 secretion by ELISA. Serum from WT mice injected with VV was found to contain significant levels of IL-6, whereas no IL-6 secretion was detected in the uninfected WT mice ( Figure 4A ).
However, IL-6 levels were significantly reduced in VV-infected TLR2 -/-or MyD88 -/-mice (p <0.001, Figure 4A ). Similar to the in vitro studies (Figure 3 ), there was no inherent defect in producing IL-6 by TLR2 -/-mice in vivo as TLR2 -/-mice treated with LPS secreted similar levels of IL-6 compared to the WT mice ( Figure 4A ). Thus, the secretion of IL-6 upon VV infection in vivo also required an intact TLR2 signaling pathway. By contrast, the production of IFN-β was independent of TLR2 or MyD88 as comparable levels of IFN-β was detected in TLR2 -/-or MyD88 -/-mice compared to the WT mice upon VV infection in vivo ( Figure 4B ).
We then asked if TLR2/MyD88 pathway was required for innate immune control of VV infection in vivo. 1 x 10 7 pfu of VV were injected intraperitoneally into female WT, TLR2 -/-or MyD88 -/-mice. 3 days later, the viral load in the ovaries was determined by the plaque assay.
Significantly (p < 0.001) higher VV titer was detected in TLR-2 -/-or MyD88 -/-mice than the WT control ( Figure 4C ). As adaptive immunity against VV had yet to be elicited at 3 days after infection (data not shown), these results suggested that the TLR2/MyD88 pathway was critical in innate immune control of VV infection in vivo. Figure 5B ). Splenocytes were also analyzed for virusspecific CD8 effectors using IFN-γ intracellular staining. In VV-infected WT mice, about 9% of total lymphocytes are IFN-γ-secreting CD8 T cells compared to only 0.16% in uninfected mice ( Figure 5C ). However, in TLR2 -/-or MyD88 -/-mice, the percentage of effector CD8 T cells was significantly reduced (p < 0.001, Figure 5C ). Co-administration of LPS to TLR2 -/-mice significantly For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
Discussion
In this paper, we demonstrated that VV activated innate immunity through a TLR2/MyD88-dependent pathway, resulting in the production of pro-inflammatory cytokines, and a TLRindependent pathway, leading to the induction of IFN-β in vitro and in vivo. More importantly, both innate immune pathways were critical for both innate and adaptive immunity against VV infection in vivo. , and TLR9 in HSV infection 27, 28 . Our data provide the first evidence that innate immune recognition of VV is mediated by TLR2 in a MyD88-dependent manner. The biological significance of this innate immune pathway lies in its critical role in both innate and adaptive immunity to VV in vivo. The mechanism(s) underlying TLR2/MyD88-dependent innate immune control of VV infection in vivo remains to be further defined. However, it appears not to be mediated by type I IFNs since no significant reduction of IFN-β was observed in TLR-2 -/-or MyD88 -/-mice ( Figure 4B ). Similarly, besides promoting DC maturation ( Figure 5A ), it is not entirely clear how the TLR2/MyD88 pathway contributes to the activation of adaptive immunity to VV. Recent observations by others and our group suggest that this may be mediated through TLR2-induced pro-inflammatory cytokines such as IL-6 and IL-1, which render naïve T cells refractory to T Reg -mediated suppression 11, 29, 30 . Another question that remains to be answered is which component(s) of VV activates TLR2 signaling pathway. Our observation that UV-VV elicited similar response to live VV suggests that input VV envelope or core protein(s) rather than newly synthesized viral product after infection may trigger the TLR2 pathway. Thus, it will be important to identify the envelope or core protein(s) of VV that activates the TLR2 pathway. Identification of such a protein(s) will help in the design of effective vaccines.
We further demonstrated that VV also activated a TLR-independent pathway leading to production of IFN-β. In addition to TLR-dependent innate immune recognition, accumulating evidence has shown the existence of TLR-independent recognition of pathogens 13 .
It has been
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From shown that viral dsRNA can activate innate immunity mediated by an intracellular sensor, RIG-1, leading to the production of type I IFNs through an IPS-1/TBK1-dependent, but TLR3-independent pathway 31 . In addition, dsDNA can also trigger the production of type I IFNs in a TLR-independent manner 32, 33 . Furthermore, NOD (nucleotide binding oligomerization domain)-containing proteins have been implicated in the recognition of bacteria independent of TLRs, leading to activation of caspase-1, which promotes the conversion of pro-cytokines such as pro-IL-1β to mature cytokines 34 . This process is catalyzed by a complex of proteins designated as inflammasome 35 . It is not clear whether the TLR-independent recognition of VV is mediated by viral DNA or other mechanisms. Thus, future studies should focus on delineation of the mechanisms underlying TLR-independent recognition of VV.
In vivo, plasmacytoid DCs (pDCs) have been shown to produce large amounts of IFN-α mediated by TLR7, TLR8 or TLR9 in response to various viral infections 36 . However, our observation that innate immune recognition of VV is mediated by TLR2 and that production of IFN-β is TLR-independent suggest that pDCs are unlikely the producers of IFN-β upon VV infection. Indeed, recent studies have shown that conventional DCs and macrophages can become potent producers of type I IFNs upon viral infection 37, 38 . Our data that bone marrow- .
In conclusion, we have shown that VV elicits innate immune response through the TLR2/MyD88-dependent pathway, which plays a critical role in activating innate and adaptive immunity to VV. We have further identified that VV also triggers a TLR-independent pathway leading to the production of IFN-β, which is essential for effective innate and adaptive immune responses to VV in vivo. These results indicate that one pathogen can target both TLR and non-TLR innate immune pathways to maximize activation of host defense and suggest potential new strategies for the design of effective vaccines.
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